---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-345753"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2026-08-12T11:35:26+00:00"
generated_at: "2026-08-12T11:40:05.843549+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xilio reports Q2 2026 results; FDA clears IND for XTX501 bispecific PD-1/masked IL-2

## Summary
- FDA cleared IND for XTX501 (bispecific PD-1/masked IL-2); Phase 1/2 dosing expected 2H 2026 in NSCLC and solid tumors; initial data 2H 2027.
- Cash and equivalents $136.0M at 6/30/26 vs $137.5M at 12/31/25; runway into Q1 2028 (excl. warrant proceeds and milestones).
- Q2 2026 collaboration revenue $18.7M vs $8.1M YoY; net loss $6.4M vs $15.8M YoY.
- IND-enabling studies for masked TCEs targeting CLDN18.2 and PSMA+STEAP1; INDs planned 2H 2027.
- Appointed Ben Harshbarger as Chief Legal Officer in June 2026.

## SEC filing metadata
- accession: 0001193125-26-345753
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2026-08-12T11:35:26+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312526345753/0001193125-26-345753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312526345753/xlo-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-345753
- JSON: https://secwatch.observer/filing/0001193125-26-345753.json
- Plain text: https://secwatch.observer/filing/0001193125-26-345753.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.